EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparison of Real-World Outcomes in Patients With Follicular Lymphoma Treated With BR Versus RCHOP-Like Regimens

Kelsey Baron, Eric Anto, John Esther, Victoria A Vardell, Lisa Pappas, Allison Bock, Daniel A Ermann, Lindsey A Fitzgerald, Boyu Hu, Harsh R Shah

Clinical Lymphoma Myeloma and Leukemia · 2025

DOI: 10.1016/j.clml.2025.03.017 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Kelsey Baron und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology & Hematologic Malignancies, Huntsman Cancer Institute/University of Utah, Salt Lake City, UT, 84112. Electronic address: Kelse…. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Antineoplastic Combined Chemotherapy Protocols, Rituximab. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Patients with follicular lymphoma (FL) grade (G) 1-3A who meet treatment criteria are commonly treated with chemo-immunotherapy regimens such as bendamustine plus rituximab (BR) or rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone (RCHOP). Two prospective trials have compared BR to RCHOP-like regimens and showed improved progression free survival with BR in FL G1-2 patients. However, in real-world practice, there is clinical variability in utilization of BR versus RCHOP-like regimens. Additionally, the optimal treatment for patients with FL G3A remains unclear. METHODS: We used a nationwide electronic health record-derived de-identified database to compare outcomes in 2089 patients with FL G1-3A treated with frontline BR versus RCHOP-like regimens. RESULTS: We demonstrated clinical improvement in time to next treatment or death (TTNTD) with BR (median 96 vs. 78 months, HR 1.15, 95% CI 0.986-1.332, P = .086), albeit not statistically significant. No difference in overall survival (OS) was observed. Maintenance rituximab was associated with improved TTNTD and OS. Among G3A patients (N = 304), TTNTD was comparable between the 2 regimens, however OS was significantly improved with RCHOP-like regimens in univariate analysis (median 138 vs. 96 months, HR 0.51, 95% CI 0.313-0.834, P = .007). CONCLUSIONS: In conclusion, this study of real-world patients supports the use of BR and rituximab maintenance for front-line treatment of FL. Further prospective studies are needed to determine the ideal treatment for FL G3A.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, FollicularAntineoplastic Combined Chemotherapy ProtocolsRituximabHumansMaleFemaleMiddle AgedAgedVincristinePrednisoneDoxorubicinCyclophosphamideTreatment OutcomeBendamustine HydrochlorideAdultAged, 80 and over

Stichwörter der Autor:innen

Chemoimmunotherapy in FLGrade 3A FLMaintenance rituximabOutcomes in FLTreatment naive FL

Substanzen

RituximabVincristinePrednisoneDoxorubicinCyclophosphamideBendamustine Hydrochloride

Autor:innen und Institutionen

  • Division of Hematology & Hematologic Malignancies, Huntsman Cancer Institute/University of Utah, Salt Lake City, UT, 84112. Electronic address: Kelsey.baron@hsc.utah.edu.
  • Department of Population Health Sciences, University of Utah, Salt Lake City, UT 84108.
  • Division of Hematology & Hematologic Malignancies, Huntsman Cancer Institute/University of Utah, Salt Lake City, UT, 84112.

Förderung

  • AbbVie

Zitieren

APA

Baron, K., Anto, E., Esther, J., Vardell, V. A., Pappas, L., Bock, A., Ermann, D. A., Fitzgerald, L. A., Hu, B., & Shah, H. R. (2025). Comparison of Real-World Outcomes in Patients With Follicular Lymphoma Treated With BR Versus RCHOP-Like Regimens. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.03.017

Vancouver

Baron K, Anto E, Esther J, Vardell VA, Pappas L, Bock A, et al. Comparison of Real-World Outcomes in Patients With Follicular Lymphoma Treated With BR Versus RCHOP-Like Regimens. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.03.017

BibTeX
@article{Baron2025,
  author = {Baron, Kelsey and Anto, Eric and Esther, John and Vardell, Victoria A and Pappas, Lisa and Bock, Allison and Ermann, Daniel A and Fitzgerald, Lindsey A and Hu, Boyu and Shah, Harsh R},
  title = {Comparison of Real-World Outcomes in Patients With Follicular Lymphoma Treated With BR Versus RCHOP-Like Regimens},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  doi = {10.1016/j.clml.2025.03.017}
}
Kostenlos starten →